Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06250140
Other study ID # ShenzhenH
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 1, 2024
Est. completion date August 1, 2024

Study information

Verified date January 2024
Source Shenzhen Hospital of Southern Medical University
Contact Ying Zhu Ying Zhu, Professor
Phone +86 13384662039
Email zhuying1@smu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

2.1 Main objective: To observe the short-term and long-term recurrence rates of various endoscopic minimally invasive treatment methods for internal hemorrhoids and different time points of endoscopic minimally invasive treatment for internal hemorrhoids in patients with grade I-III internal hemorrhoids 2.2 Secondary objective: To observe the safety and efficacy of endoscopic minimally invasive treatment of internal hemorrhoids


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 900
Est. completion date August 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. Age =18 years old, both sexes 2, grade I-III internal hemorrhoids with symptoms related to internal hemorrhoids 3. The purpose and adverse consequences of endoscopic minimally invasive treatment of internal hemorrhoids have been fully understood before surgery, and the informed consent for endoscopic minimally invasive treatment of internal hemorrhoids has been signed Exclusion Criteria: - 1. Patients with contraindications to endoscopic minimally invasive treatment (1) grade IV internal hemorrhoids, mixed hemorrhoids and external hemorrhoids; (2) I-III Degree of internal hemorrhoids with incarceration, thrombosis, erosion, infection, etc. (3) patients with severe systemic diseases could not tolerate endoscopic treatment; (4) accompanied by crissum infectious disease, anal fistula, and inflammatory bowel disease activity, etc.; (5) in menstrual period, pregnancy and puerperium, (6) patients with sclerotherapy allergy; (7) function of blood coagulation disorder or are using anticoagulant drugs. 2. Patients with a history of allergy to narcotic drugs 3. Patients who were deemed by the investigator to be ineligible for participation in the trial

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Tie up device
The recurrence rate of internal hemorrhoids in different treatment methods

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Shenzhen Hospital of Southern Medical University 964 hospital of joint Logistics Support Force, The Chinese people's liberation army army medical center

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence rate of minimally invasive endoscopic treatment If patients with internal hemorrhoids recurred with preoperative clinical symptoms (bleeding, prolapse, pain, etc.), which could not be relieved by conservative treatment, and needed endoscopic sclerotherapy, ligation, ligation sclerotherapy or surgery again, the recurrence rate = the number of recurrent cases/the number of patients X100% One year
Secondary The overall efficacy of various treatment methods (1) Cure: the symptoms of hematochezia and prolapse disappeared completely. (2) Remarkable effect: the symptoms of hematochezia and prolapse were significantly improved, or the symptoms were alleviated but the frequency and degree of attack were reduced compared with those before operation; (3) Ineffective: the symptoms of hematochezia and prolapse were not relieved or even aggravated. Total effective rate = (cure + marked effective)/total ratio X100% One year
Secondary Recurrence rates of various treatment modalities in different grades One year
Secondary The efficacy of sequential treatment after recurrence was evaluated Patients with internal hemorrhoids who had preoperative clinical symptoms (bleeding, prolapse, pain, etc.) at more than 3 months after operation, and failed to be relieved by conservative treatment, needed endoscopic sclerotherapy, ligation, ligation sclerotherapy or surgery again were regarded as recurrence. Total effective rate = (cure + marked effective)/total ratio X100% One year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06031740 - A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids N/A
Recruiting NCT06106269 - Outcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids
Recruiting NCT03917056 - Cap-assisted Endoscopic Sclerotherapy for Internal Hemorrhoids and Rectal Prolapse N/A
Recruiting NCT04169152 - CAES for Internal Hemorrhoids and Rectal Prolapse